Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin. / Shin, J S; Stopyra, G A; Warhol, M J; Multhaupt, H A.

In: Journal of Histochemistry and Cytochemistry, Vol. 49, No. 6, 2001, p. 791-2.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Shin, JS, Stopyra, GA, Warhol, MJ & Multhaupt, HA 2001, 'Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin.', Journal of Histochemistry and Cytochemistry, vol. 49, no. 6, pp. 791-2.

APA

Shin, J. S., Stopyra, G. A., Warhol, M. J., & Multhaupt, H. A. (2001). Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin. Journal of Histochemistry and Cytochemistry, 49(6), 791-2.

Vancouver

Shin JS, Stopyra GA, Warhol MJ, Multhaupt HA. Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin. Journal of Histochemistry and Cytochemistry. 2001;49(6):791-2.

Author

Shin, J S ; Stopyra, G A ; Warhol, M J ; Multhaupt, H A. / Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin. In: Journal of Histochemistry and Cytochemistry. 2001 ; Vol. 49, No. 6. pp. 791-2.

Bibtex

@article{adb02d305d3f11dd8d9f000ea68e967b,
title = "Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin.",
abstract = "Plasmacytomas are localized neoplastic proliferations of monoclonal plasma cells. When multifocal, the process is referred to as multiple myeloma. These lesions exhibit a pattern of antigen expression and cytomorphology that usually leads to a ready diagnosis. However, potentially troublesome variations in immunophenotype occur. We describe a case of a plasmacytoma from a patient who presented with sudden onset of pain and a lytic lesion of the left proximal humerus. Hematoxylin and eosin-stained sections showed a lymphoproliferative lesion composed of large lymphoid cells, some with plasmacytoid and immunoblastic features. The lesion also showed significant mitotic activity. Immunohistochemical staining was positive for CD45 (LCA), CD56 (N-CAM), CD43 (MT1), and cytokeratin CAM5.2. There was also clonal staining for lambda light chains. In addition, flow cytometric analysis showed positivity for myeloid markers such as CD13, CD33, CD38, and CD138. Significant negative markers include CD20 (L26), CD45RO (UCHL-1), and CD79alpha. The unusual phenotypic features of this plasmacytoma illustrate potential diagnostic pitfalls. It is important to fully study such lesions to correctly classify them, because this has significant impact on prognosis and management.",
author = "Shin, {J S} and Stopyra, {G A} and Warhol, {M J} and Multhaupt, {H A}",
note = "Keywords: Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Bone Neoplasms; Humans; Humerus; Immunophenotyping; Keratins; Plasmacytoma",
year = "2001",
language = "English",
volume = "49",
pages = "791--2",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "SAGE Publications",
number = "6",

}

RIS

TY - JOUR

T1 - Plasmacytoma with aberrant expression of myeloid markers, T-cell markers, and cytokeratin.

AU - Shin, J S

AU - Stopyra, G A

AU - Warhol, M J

AU - Multhaupt, H A

N1 - Keywords: Antigens, Differentiation, T-Lymphocyte; Antigens, Neoplasm; Bone Neoplasms; Humans; Humerus; Immunophenotyping; Keratins; Plasmacytoma

PY - 2001

Y1 - 2001

N2 - Plasmacytomas are localized neoplastic proliferations of monoclonal plasma cells. When multifocal, the process is referred to as multiple myeloma. These lesions exhibit a pattern of antigen expression and cytomorphology that usually leads to a ready diagnosis. However, potentially troublesome variations in immunophenotype occur. We describe a case of a plasmacytoma from a patient who presented with sudden onset of pain and a lytic lesion of the left proximal humerus. Hematoxylin and eosin-stained sections showed a lymphoproliferative lesion composed of large lymphoid cells, some with plasmacytoid and immunoblastic features. The lesion also showed significant mitotic activity. Immunohistochemical staining was positive for CD45 (LCA), CD56 (N-CAM), CD43 (MT1), and cytokeratin CAM5.2. There was also clonal staining for lambda light chains. In addition, flow cytometric analysis showed positivity for myeloid markers such as CD13, CD33, CD38, and CD138. Significant negative markers include CD20 (L26), CD45RO (UCHL-1), and CD79alpha. The unusual phenotypic features of this plasmacytoma illustrate potential diagnostic pitfalls. It is important to fully study such lesions to correctly classify them, because this has significant impact on prognosis and management.

AB - Plasmacytomas are localized neoplastic proliferations of monoclonal plasma cells. When multifocal, the process is referred to as multiple myeloma. These lesions exhibit a pattern of antigen expression and cytomorphology that usually leads to a ready diagnosis. However, potentially troublesome variations in immunophenotype occur. We describe a case of a plasmacytoma from a patient who presented with sudden onset of pain and a lytic lesion of the left proximal humerus. Hematoxylin and eosin-stained sections showed a lymphoproliferative lesion composed of large lymphoid cells, some with plasmacytoid and immunoblastic features. The lesion also showed significant mitotic activity. Immunohistochemical staining was positive for CD45 (LCA), CD56 (N-CAM), CD43 (MT1), and cytokeratin CAM5.2. There was also clonal staining for lambda light chains. In addition, flow cytometric analysis showed positivity for myeloid markers such as CD13, CD33, CD38, and CD138. Significant negative markers include CD20 (L26), CD45RO (UCHL-1), and CD79alpha. The unusual phenotypic features of this plasmacytoma illustrate potential diagnostic pitfalls. It is important to fully study such lesions to correctly classify them, because this has significant impact on prognosis and management.

M3 - Journal article

C2 - 11373326

VL - 49

SP - 791

EP - 792

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 6

ER -

ID: 5240239